Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00914537 · ClinicalTrials.gov registry record
Anal Cancer Screening Study
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 363
- Enrollment target
NCT00914537: Completed study, sponsored by National Cancer Institute (NCI).
NCT00914537 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 363 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00914537 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 363 participants
- Enrollment target
Study Summary
Background: * HIV-positive men who have sex with men (MSM) have rates of anal cancer that approach those of cervical cancer in women. However, unlike cervical cancer, there is no current recommended method of screening that could be used to detect anal precancerous lesions for the prevention of anal cancer in HIV-positive MSM. * Infections by human papillomavirus (HPV) are the likely cause of cervical and anal precancer and cancer. Detecting the presence of HPV or related biomarkers has helped to identify women who may be at increased risk of cervical cancer; researchers believe that early detection of HPV or related biomarkers in MSM may be useful for anal cancer screening. Objectives: \- To evaluate the effectiveness of various tests to detect cancer-causing HPV in HIV-positive men who have sex with men. Eligibility: \- HIV-positive MSM that are interested in receiving anal screening for precancer Design: * HIV-positive MSM will respond to a self-administered risk factor questionnaire, and will undergo a physical exam and a high-resolution anoscopy at the participating clinic. * The clinician will then collect to anal Pap specimens from each subject for research on HPV and related biomarkers. * Participants will be followed annually for 2 years to collect additional health data for research follow-up.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 363 participants |
| Start Date | 2009-06-02 |
| Est. Completion | 2020-11-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00914537
The ClinicalTrials.gov registry entry for NCT00914537 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 363 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00914537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00914537 about?
NCT00914537 is a clinical study titled "Anal Cancer Screening Study". Background: * HIV-positive men who have sex with men (MSM) have rates of anal cancer that approach those of cervical cancer in women. However, unlike cervical cancer, there is no current recommended method of screening that could be used to detect anal precancerous lesions for the prevention of ana...
What is the current status of trial NCT00914537?
This trial is currently completed. The enrollment target is 363 participants. The study started on 2009-06-02. Estimated completion is 2020-11-04.
Who is sponsoring clinical trial NCT00914537?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.